Navigation Links
TriReme Medical, Inc. Receives CE Marking for Glider(TM) PTCA Dilatation Catheter

PLEASANTON, Calif., July 30 /PRNewswire/ -- TriReme Medical, Inc. (TMI) announced today CE mark approval of its second product, a novel coronary dilatation catheter, designed to improve the treatment of patients with complex coronary disease at or near side branches. The product will be marketed under the name Glider(TM).

The Glider(TM) is a first-in-class balloon dilatation catheter with a torquable shaft and novel tip design. These features permit the Glider(TM) to cross through tight lesions and stent struts. In addition, its unique balloon characteristics were designed to allow full dilatation of the side branch ostium and reduce the risk of dissections and side branch injuries.

"Conventional balloon catheters are not optimized to cross into side branches or to fully treat the ostium of the side branch. The unique characteristics of the Glider(TM) are designed to overcome these limitations," said Professor Carlo Di Mario from the Royal Brompton Hospital in London. "I am pleased to be working with TriReme as they develop products specifically tailored for the treatment of bifurcation disease."

"The Glider(TM) dilatation catheter follows the success of our Antares(R) stent system and is another important product in TriReme's toolbox enabling treatment of a broad range of bifurcation lesions," said Eitan Konstantino, Ph.D., President and Chief Executive Officer of TMI. "We are committed to developing a series of innovative products that will enable the best possible treatment for patients suffering from complex arterial disease."

About Bifurcation Disease

Approximately 20% of all atherosclerosis cases involve lesions at or near side branches in the coronary tree. Acute and long term outcomes in this subset of patients are worse than the outcomes of patients with simple lesions. Moreover, when percutaneously treating bifurcation lesions, interventional cardiologists use a variety of complex techniques that involve the modification and distortion of tubular stents designed for straight rather than branching arteries. To date in the US, no stents are approved for use in bifurcations. For these reasons, bifurcation lesions are common reasons for referral to coronary bypass surgery.

About TriReme Medical, Inc.

TriReme Medical, Inc. (TMI) is a privately held medical device company. TMI is based in California and dedicated to the development and manufacturing of novel stent technology and other devices for the treatment of atherosclerotic disease at or near bifurcations.

In April 2009, TriReme received CE mark for its Antares(R) SX stent system. Antares(R) is a main vessel stent that is designed to adapt to a broad variety of bifurcation lesions and coronary anatomies to produce predictable results during provisional stenting. To date, Antares(R) has been used in over 100 patients in Europe.

TMI can be contacted at +1 (925) 931-1300 or

SOURCE TriReme Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
4. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
5. Medical, Behavioral Woes Can Drive Dogs to Bite
6. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
7. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
8. Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
11. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
Post Your Comments:
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a ... customers 10% off of their purchase of lice treatment product. In addition, customers will ... to a company spokesperson. “Finding lice is a sure way to ruin the holidays, ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ProSidebar: ... in Final Cut Pro X. With ProSidebar: Fasion, video editors can easily add ... ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop zones, lines, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the Radiology ... Building Better Radiology Marketing Programs meeting will showcase some of the best ... at Caesars Palace in Las Vegas with a pre-conference session on a collaborative ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Japanese therapeutic drug monitoring market, ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
Breaking Medicine Technology: